$vTv Therapeutics (VTVT.US)$
FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M

$vTv Therapeutics (VTVT.US)$
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Monday, 17th March at 8:30 am
Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes
CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months
HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ: VTVT), a clinical stage ...

$vTv Therapeutics (VTVT.US)$
FDA Green Light: vTv's Revolutionary Oral Diabetes Drug Back on Track with Faster Timeline

$vTv Therapeutics (VTVT.US)$
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
Monday, 9th December at 7:33 am
WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug D...

$vTv Therapeutics (VTVT.US)$
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

$vTv Therapeutics (VTVT.US)$ 25

$vTv Therapeutics (VTVT.US)$ 48